They all demonstrated that MBC seemed to resemble T1a invasive BC with more aggressive characteristics such as ER− (22.9–33.1%), HER2+ (10.5–36.5%), higher LNM rate (7.6–9.6%), and worse outcomes than that of pure DCIS. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.